SynthesisDiabetes, obesity & metabolism2026

Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.

Dongjin Yeo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.